KFAS
SUPN icon

Keating Financial Advisory Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Keating Financial Advisory Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44K Buy
74
+1
+1% +$48 ﹤0.01% 1717
2026
Q1 		$3.77K Buy
73
+61
+508% +$3.11K ﹤0.01% 1585
2025
Q4 		$596 Buy
+12
New +$583 ﹤0.01% 1918

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Keating Financial Advisory Services's SUPN Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Supernus Pharmaceuticals (SUPN) stake by 1.4% in Q2 2026, buying an estimated $48 and bringing the position to 74 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

Keating Financial Advisory Services first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.77K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Keating Financial Advisory Services held 74 shares of Supernus Pharmaceuticals worth $3.44K as of Q2 2026.
  • Keating Financial Advisory Services bought 1 Supernus Pharmaceuticals share in Q2 2026, an estimated $48.
  • Supernus Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1717 holding.
  • Keating Financial Advisory Services first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Supernus Pharmaceuticals position peaked at $3.77K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.